Q2 2020 Eris Lifesciences Ltd Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Eris Lifesciences Q2 FY '20 Results Conference Call. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Mr. Amit Bakshi, Managing Director. Thank you, and over to you.
Hello. I welcome everyone and thank you for joining for this call.
Let me begin by taking you through the presentation that we uploaded and then we can open for Q&A.
So far the quarter, we've grown by 9.4% versus -- what IPM, stood at 11.5% growth. In our Chronic and Sub Chronic therapy, which comprises around 86% of our business, we have grown 11.4% versus 10.6% for the IPM.
On -- we've also shared the secondary numbers for H1 '20, where the trend continues of Eris outperforming IPM in chronic, sub chronic segments. We also continue to have high ranks among our key specialties, fourth with cardiologists, third with diabetologists, gastroenterologists as well as neurologists.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
